

Peer Review File

Article information: <https://dx.doi.org/10.21037/gs-22-751>

Review Comments

- 1) First, the title needs to indicate the case who was initially resistant to or failed in HP therapy.

Reply: We have modified our text as advised

Changes in the text: Page 1, line 3

- 2) Second, the abstract needs some revisions. The background only described the clinical difficulties but did not explain the rarity, novelty, and potential unique clinical contribution of this case, so it remains unclear whether this case deserves to be reported. The case presentation is not adequate, which need to provide more data on the clinical characteristics of this case including age, sex, treatment history, efficacy outcomes and adverse events after the neoadjuvant therapy of pyrotinib plus trastuzumab and vinorelbine, follow up duration, and long-term prognosis of this case. Please briefly summarize the findings from the literature review here. The current conclusion needs detailed comments for the clinical implications of the findings from this case.

Reply: We have modified our text as advised. We added some data to explain the rarity, novelty, and potential unique clinical contribution of this case, and provided more data on the clinical characteristics of this case. We also provided detailed comments on the clinical implications of the findings from this case.

Changes in the text: Page1, line 27-36; Page2, line 1-6.

- 3) Third, in the introduction of the main text, the authors did not indicate the rarity, novelty, and potential unique clinical contribution of this case, the neoadjuvant therapy of pyrotinib plus trastuzumab and vinorelbine. The authors need to provide insight on the clinical importance and contribution of this case.

Reply: We have modified our text as advised. In the introduction of the main text, we added some data to explain the rarity, novelty, and potential unique clinical contribution of this case, and provided insight on the clinical importance and contribution of this case.

Changes in the text: Page 2, line30-32, 36,37; Page 3, line 1-8, 14-29.

4) Fourth, in the case presentation, a timeline figure is needed to briefly summarize the history, diagnosis, staging, the neoadjuvant treatment with pyrotinib plus trastuzumab and vinorelbine, efficacy outcomes, progression, follow up, and long-term prognosis of this case. In the discussion, please use a separated paragraph to summarize the findings from the literature review.

Reply: We added a timeline figure as advised; We added a separated paragraph to summarize the findings from the literature review as advised.

Changes in the text: Page 11, line 10-11, Figure 4; Page 5, line24-36 and Page 6, line 1-3.